Humana Inc. $HUM Shares Sold by Rafferty Asset Management LLC

Key Points

• Rafferty Asset Management LLC reduced its stake in Humana Inc. by 18.2% during the first quarter, selling 2,489 shares for a total holding of 11,170 shares valued at approximately $2.96 million.
• Humana reported a quarterly earnings miss with $6.27 EPS, which was below the consensus estimate of $6.32, despite a 9.6% increase in revenue year-over-year to $32.39 billion.
• The company announced a quarterly dividend of $0.885 per share, set to be paid on October 31st, with a dividend yield of approximately 1.2%.

Rafferty Asset Management LLC lowered its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 18.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,170 shares of the insurance provider's stock after selling 2,489 shares during the period. Rafferty Asset Management LLC's holdings in Humana were worth $2,956,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Revolve Wealth Partners LLC purchased a new position in shares of Humana in the fourth quarter valued at approximately $202,000. Solel Partners LP acquired a new position in Humana in the 4th quarter valued at $1,116,000. Accredited Wealth Management LLC purchased a new position in Humana in the 4th quarter valued at $101,000. Aptus Capital Advisors LLC boosted its stake in Humana by 12.0% during the 4th quarter. Aptus Capital Advisors LLC now owns 859 shares of the insurance provider's stock worth $218,000 after purchasing an additional 92 shares during the last quarter. Finally, Cary Street Partners Financial LLC acquired a new stake in shares of Humana in the fourth quarter valued at about $694,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Trading Up 0.9%

NYSE:HUM traded up $2.74 on Wednesday, reaching $312.80. The company's stock had a trading volume of 972,629 shares, compared to its average volume of 1,701,299. Humana Inc. has a 12-month low of $206.87 and a 12-month high of $382.72. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69. The firm has a market cap of $37.62 billion, a price-to-earnings ratio of 24.04, a price-to-earnings-growth ratio of 1.79 and a beta of 0.44. The stock has a 50 day moving average price of $257.24 and a 200 day moving average price of $255.32.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. During the same period in the previous year, the firm posted $6.96 earnings per share. The company's quarterly revenue was up 9.6% compared to the same quarter last year. Humana has set its FY 2025 guidance at 17.000- EPS. On average, equities analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.1%. Humana's payout ratio is presently 27.17%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Piper Sandler lowered their price target on shares of Humana from $288.00 to $272.00 and set a "neutral" rating on the stock in a research report on Thursday, July 31st. Wall Street Zen cut Humana from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Bank of America lifted their price objective on Humana from $285.00 to $312.00 and gave the stock a "neutral" rating in a research report on Tuesday. Morgan Stanley dropped their target price on Humana from $290.00 to $277.00 and set an "equal weight" rating for the company in a report on Thursday, July 31st. Finally, Robert W. Baird cut their target price on Humana from $300.00 to $297.00 and set a "neutral" rating for the company in a research note on Friday, July 25th. Seven analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Humana currently has an average rating of "Hold" and a consensus target price of $285.76.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.